Pricing Strategy & MFN
In a post-MFN environment, pricing decisions in one market are increasingly important to pricing, access and launch strategies elsewhere. Integrated scenario forecasting can help organisations make more informed global decisions on pricing, access and launch.
How do you build an effective global pricing and launch strategy post-MFN?
MFN policies and international reference pricing have increased the complexity of global pricing strategy.
Pricing, reimbursement and launch decisions made in one market can influence opportunities elsewhere, creating new challenges for value preservation, launch sequencing and market access planning.
Understanding these potential interdependencies earlier can help organisations evaluate pricing scenarios and make more informed strategic decisions.
Powered by Lightning Insights and SyMAP
We combine stakeholder insight with analytics powered by SyMAP, the global pricing and forecasting platform from our partner Symaptics. Together, these capabilities help clients evaluate pricing and launch scenarios, assess reference pricing and MFN implications, and make informed decisions across global markets.
Lightning Insights stakeholder perspectives and market insight
Access perspectives from payers, clinicians and health economic advisors across global markets.
SyMAP pricing analytics
Analyse pricing dynamics, reference pricing exposure and commercial risk scenarios.
IRP and MFN integrated modelling
Model potential pricing implications across international reference pricing and MFN frameworks.
Launch sequencing assessment
Evaluate how launch timing and market sequencing may influence future value.
Strategic recommendations
Translate insights into practical recommendations that support pricing and access decisions.
Evaluating your global pricing strategy
MFN could affect a wide range of launches, although some may be exempt depending on the pricing model or agreement in place. It is critical to continually pressure test your pricing, access and launch strategy to understand and manage potential MFN exposure.
Pricing sensitivities depend on a number of factors, including launch sequencing and gross-to-net assumptions. Validating the inputs to forecasting frameworks is a vital first step in understanding global pricing exposure.
Launch sequencing is a powerful tool for recognising commercial value and can make the difference to both global net revenues and overall MFN risk.
As many as possible. Limiting uncertainty and pressure testing in-market scenarios are paramount to developing an effective commercial strategy.
Patient access is paramount, alongside return on investment. The best strategies balance equitable access with realised value, striking the right balance between payer and clinical value.
How we approach pricing challenges
Applying our guiding framework, Explore • Build • Optimise, we help organisations assess pricing risks, evaluate evolving scenarios, and make better informed pricing and access decisions
Explore
Assess IRP and MFN exposure, identify key pricing and market dynamics, and understand the commercial and access implications across global markets.
Build
Develop and stress-test pricing and launch scenarios and strategies, including international reference pricing, MFN exposure, rebate analysis and revenue implications.
Optimise
Refine pricing and launch sequencing strategies to protect value, align with commercial objectives and support patient access
Assessing MFN and IRP implications?
Whether you're assessing potential MFN exposure, evaluating pricing scenarios or refining launch sequencing decisions, we're here to help.
Pricing strategy case studies
Explore how we've supported clients in evaluating MFN exposure and pricing scenarios.
Pricing strategy (including international referencing implications) for a new orphan therapy for a neurological disorder
